RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
International Stem Cell Stock

International Stem Cell P/E 2024

International Stem Cell P/E

-9.78

Ticker

ISCO

ISIN

US4603782016

As of Jul 12, 2024, International Stem Cell's P/E ratio was -9.78, a -18.77% change from the -12.04 P/E ratio recorded in the previous year.

The International Stem Cell P/E history

International Stem Cell Aktienanalyse

What does International Stem Cell do?

International Stem Cell Corp (ISCO) is a biotechnology company founded in 2005 and headquartered in Carlsbad, California. It specializes in the development and manufacture of stem cell products for therapeutics and research purposes. ISCO specializes in the production of "human parthenogenetic stem cells" (hpSCs). This means that they produce stem cells from human egg cells that can replicate without fertilization by sperm. The company is a leader in this field and has filed over 80 patents worldwide. ISCO has various business areas, including life science research, therapeutics, dermatology, and animal health. The company partners with various industries, including academic institutions, pharmaceutical and biotechnology companies, and government agencies. One of their biggest partnerships is with the Chinese company Sino Biopharmaceuticals. ISCO offers a variety of products, including in vitro diagnostics for testing genetic diseases such as Huntington's and food allergies. However, the diagnostics division of the company is a small department primarily focused on research and development purposes. ISCO also has a dermatology division called Lifeline Skin Care, which manufactures skincare products based on human stem cells. These products have been developed for improving skin texture and reducing scars. Lifeline Skin Care is a luxury brand for skincare products currently sold in over 15 countries worldwide. In terms of animal health, ISCO recently launched a new division called Lifeline Animal Health. They are developing animal therapeutics based on hpSCs. The company has already developed the first animal therapeutic for dogs approved for the treatment of hip dysplasia. However, ISCO primarily focuses on the development of therapeutics for human stem cells. The company aims to be a global leader in the development of stem cell therapeutics. Their first product, CytoCor for heart disease, is already in clinical phase 1b/2a. The drug is intended to help reduce damage after a heart attack and improve heart function. ISCO also plans to develop therapeutics for other indications, including Alzheimer's disease, based on hpSCs. The company has a strong partnership with the California Institute for Regenerative Medicine, which focuses on stem cell research and their use in medicine. ISCO is a leading company in stem cell research and development. They have a unique approach to stem cell production and offer a variety of products and services for various industries. The company aims to develop groundbreaking stem cell therapeutics and change the way diseases are treated. International Stem Cell ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering International Stem Cell's P/E Ratio

The Price to Earnings (P/E) Ratio of International Stem Cell is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing International Stem Cell's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of International Stem Cell is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in International Stem Cell’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about International Stem Cell stock

What is the price-to-earnings ratio of International Stem Cell?

The price-earnings ratio of International Stem Cell is currently -9.78.

How has the price-earnings ratio of International Stem Cell changed compared to last year?

The price-to-earnings ratio of International Stem Cell has increased by -18.77% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of International Stem Cell high compared to other companies?

Yes, the price-to-earnings ratio of International Stem Cell is high compared to other companies.

How does an increase in the price-earnings ratio of International Stem Cell affect the company?

An increase in the price-earnings ratio of International Stem Cell would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of International Stem Cell affect the company?

A decrease in the price-earnings ratio of International Stem Cell would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of International Stem Cell?

Some factors that influence the price-earnings ratio of International Stem Cell are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does International Stem Cell pay?

Over the past 12 months, International Stem Cell paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, International Stem Cell is expected to pay a dividend of 0 USD.

What is the dividend yield of International Stem Cell?

The current dividend yield of International Stem Cell is .

When does International Stem Cell pay dividends?

International Stem Cell pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of International Stem Cell?

International Stem Cell paid dividends every year for the past 0 years.

What is the dividend of International Stem Cell?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is International Stem Cell located?

International Stem Cell is assigned to the 'Health' sector.

Wann musste ich die Aktien von International Stem Cell kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of International Stem Cell from 7/12/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/12/2024.

When did International Stem Cell pay the last dividend?

The last dividend was paid out on 7/12/2024.

What was the dividend of International Stem Cell in the year 2023?

In the year 2023, International Stem Cell distributed 0 USD as dividends.

In which currency does International Stem Cell pay out the dividend?

The dividends of International Stem Cell are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von International Stem Cell

Our stock analysis for International Stem Cell Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of International Stem Cell Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.